Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Bertram Glass, Bettina Altmann, Matthias Stelljes, Georg Lenz, Julia Marx, Justin Hasenkamp, Frank P. Kroschinsky, Anna Ossami Saidy, Peter Dreger, Lutz Peter Hermann Mueller, Inken Hilgendorf, Gerald Illerhaus, Guido Kobbe, Roland Schroers, Katrin Linke, Carsta Koehler, Norbert Schmitz, Marita Ziepert, Pearl van Heteren

Blood (2023) 142 (Supplement 1): 231.

https://doi.org/10.1182/blood-2023-173179

Published: 2023

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

Blood (2022) 140 (Supplement 1): 2083–2085.

https://doi.org/10.1182/blood-2022-168685

Published: 2022

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Blood (2021) 138 (Supplement 1): 463.

https://doi.org/10.1182/blood-2021-145097

Published: 2021

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Blood (2019) 134 (Supplement_1): 2740.

https://doi.org/10.1182/blood-2019-125584

Published: 2019

Journal Articles

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Blood (2019) 134 (19): 1608–1618.

https://doi.org/10.1182/blood.2019001425

Published: 2019

Includes: Supplemental data

Journal Articles

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Blood (2019) 133 (8): 840–851.

https://doi.org/10.1182/blood-2018-08-869453

Published: 2019

Includes: Supplemental data

Journal Articles

Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma

Vinodh Kakkassery, Roland Schroers, Sarah E. Coupland, Marc-Ilan Wunderlich, Marc Schargus, Carsten Heinz, Susanne Wasmuth, Arnd Heiligenhaus, Guido Ahle, Patrick Lenoble, Uwe Schlegel, Wolff Schmiegel, H. Burkhard Dick, Alexander Baraniskin

Blood (2017) 129 (23): 3130–3133.

https://doi.org/10.1182/blood-2017-01-765180

Published: 2017

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Sebastian Birndt, Thomas Schenk, MD, Frank M. Brunkhorst, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Markus Müller, MD, Jens P. Panse, MD, Roland Schroers, MD, Jan Braess, MD, Norbert Frickhofen, MD, Gritta Janka, MD PhD, Kai Lehmberg, MD, Andreas Hochhaus, MD, Thomas Ernst, MD, Paul La Rosée, MD

Blood (2016) 128 (22): 2523.

https://doi.org/10.1182/blood.V128.22.2523.2523

Published: 2016

Journal Articles

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

Ulrich Duehrsen, MD, Stefan P Müller, MD, Jan Rekowski, Dipl.-Stat., Bernd Hertenstein, MD, Christiane Franzius, MD, Rolf Mesters, MD, Matthias Weckesser, MD, Frank Kroschinsky, MD, Jörg Kotzerke, MD, Anke Franzke, MD, Frank M Bengel, MD, Paul La Rosée, MD, Martin Freesmeyer, MD, Heinz-Gert Hoeffkes, MD, Andreas Hertel, MD, Dirk Behringer, Gabriele Prange-Krex, MD, Martin Griesshammer, MD, Jens Holzinger, MD, Stefan Wilop, MD, Thomas Krohn, MD, Aruna Raghavachar, MD, Georg Maschmeyer, MD, Ingo Brink, MD, Roland Schroers, MD, Tobias Gaska, MD, Tu-Anh Dang, MD, Aristoteles Giagounidis, Ariane Dienst, MD, Hubertus Hautzel, MD, Ralph Naumann, MD, Alfred Klein, MD, Dennis Hahn, MD, Gabriele Pöpperl, MD, Matthias Grube, MD, Jörg Marienhagen, MD, Andreas Schwarzer, MD, Lars Kurch, MD, Thomas Höhler, MD, Heike Steiniger, MD, Holger Nückel, MD, Thomas Südhoff, MD, Wolfgang Römer, MD, Marcus Brinkmann, Claudia Ose, Dieter Hoelzer, MD, Jan Dürig, MD, Karl-Heinz Jöckel, PhD, Wolfram Klapper, MD, Andreas Hüttmann, MD

Blood (2016) 128 (22): 1857.

https://doi.org/10.1182/blood.V128.22.1857.1857

Published: 2016

Journal Articles

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Blood (2016) 128 (22): 781.

https://doi.org/10.1182/blood.V128.22.781.781

Published: 2016

Journal Articles

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

Maria Carolina Oliveira, MD PhD, Myriam Labopin, MD, Jörg Henes, MD PhD, John Moore, MD, Nicoletta Del Papa, MD PhD, Ricca Stanciu, Ioanna Sakellari, MD PhD, Roland Schroers, MD, Hans Ulrich Scherer, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof., Thomas Daikeler, MD, Tobias Alexander, Jürgen Finke, MD, Manuela Badoglio, John A Snowden, MD FRCP, FRCPath, Dominique Farge, MD PhD

Blood (2014) 124 (21): 2517.

https://doi.org/10.1182/blood.V124.21.2517.2517

Published: 2014

Journal Articles

High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group

Gerald Illerhaus, MD, Kristina Fritsch, MD, Ingo Schmidt-Wolf, MD, Roland Schroers, MD, Gerlinde Egerer, MD, Agnieszka Korfel, MD, Tobias Birnbaum, MD, Monika Lamprecht, MD, Nikolas von Bubnoff, Hans-Heinrich Wolf, MD, Stephan Stilgenbauer, MD, Martin Trepel, MD PhD, Robert Möhle, MD, Claudia Hader, MD, Gabriele Ihorst, Heidi Fricker, Benjamin Kasenda, MD, Elisabeth Schorb, MD, Jürgen Finke, MD

Blood (2014) 124 (21): 2527.

https://doi.org/10.1182/blood.V124.21.2527.2527

Published: 2014

Journal Articles

Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system

Alexander Baraniskin, Jan Kuhnhenn, Uwe Schlegel, Andrew Chan, Martina Deckert, Ralf Gold, Abdelouahid Maghnouj, Hannah Zöllner, Anke Reinacher-Schick, Wolff Schmiegel, Stephan A. Hahn, Roland Schroers

Blood (2011) 117 (11): 3140–3146.

https://doi.org/10.1182/blood-2010-09-308684

Published: 2011

Includes: Supplemental data

NARROW

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD

Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group

Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only